Biophage Pharma Appoints New Chairman and Strengthens Senior Executive.MONTREAL -- (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension .V: BUG) - Richard Sherman appointed as Chairman - Bruce Schmidt appointed as CBO CBO See: Collateralized Bond Obligation. Biophage Pharma is pleased to announce the appointments of Richard Sherman, J.D. as Chairman of the Board and Bruce Schmidt as Chief Business Officer. Mr. Schmidt will assume overall responsibilities for several of Biophage's activities, including its corporate and business development. Mr. Sherman succeeds Dr. Rosemonde Mandeville who remains Director of the Board and President and Chief Executive Officer of the Corporation. "I am very pleased that Mr. Schmidt has accepted to join our management team. He will bring close to 20 years of extensive and solid experience in the high tech and biotech sectors including the area of business development, strategic planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. and corporate management," said Dr. Rosemonde Mandeville, President and Chief Executive Officer of Biophage Pharma. "It will be a pleasure to join the management of Biophage at this important time in the Corporation's development. The Nanosensor technology and the Phage therapy Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections. Bacteriophages, or "phages" are viruses that invade only bacterial cells and, in the case of lytic have shown enormous potential and address several important unmet needs. The opportunity to develop these assets is very exiting and will have very positive long-term benefits for the company," said Mr. Bruce Schmidt. "Mr. Sherman has been an active member of the Board since 2000 and I am very proud that he has accepted to take the Chairman position. As such he will continue to bring a broader international prospective on corporate development and corporate financing. These changes reflect our growth strategy and will also help me concentrate on business strategy and products development," concluded Dr. Mandeville. About Richard Sherman Mr Sherman has worked in the biotech and pharmaceutical sectors at senior levels for over 30 years, including serving as Deputy General Counsel at SmithKline-Beckman Corporation and founder and Managing Officer of a consulting firm QED QED abbr. Latin quod erat demonstrandum (which was to be demonstrated) QED which was to be shown or proved [Latin quod erat demonstrandum] Noun 1. Technologies Inc, (now a wholly-owned subsidiary of the Omnicom Group, Inc.).He is a principal in CIP (1) (Common Isochronous Packet) The packet format used in time-based (real time) FireWire transmission. See FireWire, IEC 61883 and mLAN. (2) (Common Industrial P Capital Management, Inc. (a private investment firm) and a venture partner of Ventana Capital Management (Irvine California) and SCP (1) (Service Control Point) A node in an SS7 telephone network that provides an interface to databases, which may reside within the SCP computer or in other computers. Private Equity Partners (Philadelphia, PA).He also serves asVice-President, Secretary and General Counsel of Hawaii Biotech Inc. and as a consultant to the Honolulu law firm of Goodsill Anderson Quinn & Stifel. He has also an extensive expertise in licensing, equity investment and legal counselling and has served on several boards of private and public companies. About Bruce Schmidt Throughout his career, Mr. Schmidt has held several executive positions with pharmaceutical and biotechnology companies. He is the founder and President of IGT IGT impaired glucose tolerance. Pharma Inc. and the co-founder and advisor to Prescient pre·scient adj. 1. Of or relating to prescience. 2. Possessing prescience. [French, from Old French, from Latin praesci Neuropharma Inc. He has served as Director for ten public high tech or biotech companies, including Biophage Pharma since 2001. Mr. Schmidt is also a Founding Director of the TSX Venture listed company association, a past chairman of the B.C. Biotechnology Alliance and a founding Board member of Genome B.C. About Biophage Pharma Inc. Biophage Pharma Inc. is a Canadian biopharmaceutical company developing new therapeutic and diagnostic products using phage-based technology. Founded in 1995, Biophage is located at the Biotechnology Research Institute in Montreal and employs 15 people, including a team of 13 researchers. Through an active research and development program, as well as in-licensing and collaboration agreements, Biophage is building a portfolio of promising new therapeutics collaboration agreements, Biophage is building a portfolio of promising new therapeutics (www.biophage.com). The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. does not accept responsibility for the adequacy or accuracy of this release. Biophage Pharma Inc. (TSX VENTURE:BUG) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion